Drugs / Volenrelaxin
Volenrelaxin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04768855 | Mar 2021 → May 2022 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT06598631 | Oct → Dec 2024 | chronic kidney disease | Eli Lilly and Company | Withdrawn | No outcome recorded |
| Phase 2 | NCT05592275 | Feb 2023 → Jan 2025 | heart failure | Eli Lilly and Company | Terminated | Met primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Volenrelaxin | “Volenrelaxin is a half-life-extended recombinant human relaxin protein developed for improving kidney perfusion and cardiorenal function.” PMID 38782726 ↗ Dec 2024 |
| Known as | LY3540378 | “Volenrelaxin (LY3540378) increases renal plasma flow: a randomized Phase 1 trial.” PMID 38782726 ↗ Dec 2024 |
| Known as | Volenrelaxina | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068449 ↗ |
| Known as | Volenrelaxine | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068449 ↗ |
| Modality | Protein / enzyme biologic | “Volenrelaxin is a half-life-extended recombinant human relaxin protein” PMID 38782726 ↗ Dec 2024 |
| Route | Intravenous | “SAD participants (n = 56) received an intravenous or subcutaneous dose of volenrelaxin or placebo in a dose-ascending manner.” PMID 38782726 ↗ Dec 2024 |
| Route | Subcutaneous | “SAD participants (n = 56) received an intravenous or subcutaneous dose of volenrelaxin or placebo in a dose-ascending manner.” PMID 38782726 ↗ Dec 2024 |